Latest news
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
MedinCell is a pharmaceutical company at commercial stage. We develop a portfolio of long-acting injectables in various therapeutic areas. Our proprietary technology BEPO® aims to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier-one pharmaceutical companies and foundations to improve Global Health through new therapeutic options.
Latest news
Phase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
Session en français
Rendez-vous le mardi 2 mai à 18h30 pour une vidéoconférence dédiée à l'approbation de UZEDY™
English session
On Tuesday, May 2 at 7.30 pm (CEST) participate in our videoconference dedicated to the approval of UZEDY™
CONTACT